Evidence map›Paper›PMID 24012457›Full record

ArticleBioorganic & medicinal chemistry2013

Novel 3-nitro-1H-1,2,4-triazole-based piperazines and 2-amino-1,3-benzothiazoles as antichagasic agents.

Maria V Papadopoulou, William D Bloomer, Howard S Rosenzweig, Marcel Kaiser, Eric Chatelain, Jean-Robert Ioset

Open access · greenAbstract read
In one paragraph

Article in Bioorganic & medicinal chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 52 citations in OpenAlex.

  1. Review
  2. Heliyon · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Review on Experimental Treatment Strategies AgainstJournal of experimental pharmacology · 2021
    Review
  7. An insight on medicinal attributes of 1,2,4-triazoles.European journal of medicinal chemistry · 2020
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Antitrypanosomal activity of 5-nitro-2-aminothiazole-based compounds.European journal of medicinal chemistry · 2016
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Maria V PapadopoulouNorthShore University HealthSystem, Department of Radiation Medicine, 2650 Ridge Ave., Evanston, IL 60201, USA. Electronic address: mpapadopoulou@northshore.org.
William D Bloomer
Howard S Rosenzweig
Marcel Kaiser
Eric Chatelain
Jean-Robert Ioset
Drugs for Neglected Diseases Initiative · CHNorthShore University HealthSystem · USOakton Community College · USSwiss Tropical and Public Health Institute · CH

Funding

Drug Discovery Consortium for Chagas DiseaseR01AI082542 · NIAID · UNIVERSITY OF GEORGIA · PI TARLETON, RICK L · 2009 to 2010
$2.2M
NIAID NIH HHS 1R01AI082542-01NIAID NIH HHS R01 AI082542
6 · The paper itself

Abstract

We have previously shown that 3-nitro-1H-1,2,4-triazole-based amines demonstrate significant trypanocidal activity, in particular against Trypanosoma cruzi, the causative parasite of Chagas disease. In the present work we further expanded our research by evaluating in vitro the trypanocidal activity of nitrotriazole-based piperazines and nitrotriazole-based 2-amino-1,3-benzothiazoles to establish additional SARs. All nitrotriazole-based derivatives were active or moderately active against T. cruzi; however two of them did not fulfill the selectivity criteria. Five derivatives were active or moderately active against Trypanosoma brucei rhodesiense while one derivative was moderately active against Leishmania donovani. Active compounds against T. cruzi demonstrated selectivity indexes (toxicity to host cells/toxicity to T. cruzi amastigotes) from 117 to 1725 and 12 of 13 compounds were up to 39-fold more potent than the reference compound benznidazole. Detailed SARs are discussed.

Indexed as

AnimalsBenzothiazolesCell LineCell SurvivalLeishmania donovaniPiperazinesRatsStructure-Activity RelationshipTriazolesTrypanocidal AgentsTrypanosoma brucei bruceiTrypanosoma cruzi1,2,4-triazoleBenzothiazolesPiperazinesTriazolesTrypanocidal AgentsAntitrypanosomal agentsbenznidazole (N-benzyl-2-(2-nitro-1H-imidazol-1-yl)acetamide)BenzothiazolesBnzChagas diseaseconcentration for 50% growth inhibitionHAThuman African trypanosomiasisIC(50)Nfxnifurtimox (4-(5-nitrofurfurylindenamino)-3-methylthio-morpholine-1,1-dioxide)NitrotriazolesNTRPiperazinesSARsselectivity indexSIStructure–activity relationshipsTbNTRT. bruceiT. brucei NTRT. cruziTDRTropical diseases research (http://www.who.int/tdr/en/)Trypanosoma bruceiTrypanosoma cruzitype I nitroreductase

Identifiers

PMID24012457
PMCPMC3873001
OpenAlexW2138945086

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.